The Management Board of GLG Pharma S.A. ("Company", "Issuer") makes publicly available information on the completed private subscription for series F ordinary bearer shares of the Company ("Series F Shares"). Br> 1. The start and end date of the subscription or sale: br> Subscription of Series F Shares lasted from July 6 to July 14, 2017. The subscription for Series F Shares was made by private placement, so no subscription or share allocation was accepted. within the meaning of the Code of Commercial Companies. The series F shares were issued on July 14, 2017. br> 2. Date of financial instruments allotment: br> Due to the fact that the take-up of the F series shares was effected through private subscription, no allocation of shares within the meaning of the Code of Commercial Companies was made. The series F shares were issued on July 14, 2017. br> 3. Number of financial instruments included in the subscription or sale: br> The private subscription comprised no more than 1,300,000 series F shares. Br> 4. The rate of reduction in individual tranches in the case when even in one tranche the number of allocated financial instruments was smaller than the number of financial instruments for which subscriptions were made: br> The offer of series F shares was not divided into tranches. Due to the type of subscription the reduction did not occur. The shares were subscribed for in a private subscription, therefore no subscriptions for shares were made. Br> 5. The number of financial instruments that have been allocated as part of the subscription or sale: br> The acquisition of Series F Shares was effected through private placement, so no allocation of shares within the meaning of the Code of Commercial Companies. As part of a private subscription, 1,300,000 Series F shares were taken up. Br> 6. Price at which financial instruments were acquired (subscribed): br> Series F shares were acquired at an issue price of PLN 2.25 per share. Br> 7. Description of the method of covering the shares (determination whether the shares were taken for cash, for cash contributions in other ways or for non-cash contributions): br> Series F shares were taken up for cash. Year> 8. Number of persons who subscribed for financial instruments covered by subscription or sale in individual tranches: br> Series F shares were subscribed for in a private subscription, therefore no subscriptions for shares were made. As part of a private subscription, series F sharesthey were taken up by 10 legal persons and 19 natural persons. br> 9. Number of persons to whom financial instruments were allocated as part of a subscription or sale in individual tranches: br> The acquisition of Series F Shares was effected through private placement, therefore no allocation of shares within the meaning of the Code of Commercial Companies. The series F shares were taken up by 10 legal persons and 19 natural persons. Br> 10. The names (companies) of underwriters who took financial instruments as part of performing underwriting agreements, specifying the number of financial instruments they took, together with the actual price of the financial instrument unit (issue or sale price, after deduction of the consideration for the take-over of a financial instrument unit) underwriting agreements, acquired by the underwriter): br> There is no contract for sub-issue of series F Shares. br> 11. Total specification of the costs that have been included in the costs of issue, including the costs according to their titles along with the methods of accounting for these costs in the account books and how they are recognized in the issuer's financial statements. Br> Total estimated costs that have been included in the the costs of issuing Series F shares is PLN 254,918,00, of which: br> a. the costs of preparing and conducting the offer: PLN 209,918,00, br> b. costs of remuneration of underwriters: PLN 0.00, br> c. costs of preparing a public information document or information document, including consultancy costs: PLN 15,000.00, br> d. Promotion costs of the offer: PLN 30,000.00. br> The costs of issuing Series F Shares will decrease the Company's supplementary capital arising from the surplus of the issue value of the issued shares over their nominal value. br> Legal basis: §4 para. 1 of Annex No. 3 to the Alternative Trading System Regulations - "Current and periodic information disclosed in the alternative trading system on the NewConnect market". Br>
Source: company website, investor relations, current and periodic reports.